Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Next Previous
Trial Profile

A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavorixafor (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors X4 Pharmaceuticals

    • Most Recent Events

    • 02 Jan 2019 Status changed from recruiting to completed.
    • 18 Apr 2018 As of September 15, 2017, 13 patients have been enrolled, and 11 have completed the study, according to results presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 18 Apr 2018 Results (n=13) assessing safety and tolerability of X4P-001 in combination with Keytruda (pembrolizumab) in patients with advanced melanoma, were presented at the 109th Annual Meeting of the American Association for Cancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top